ReviewCurrent drug metabolism2015
Diallyl Sulfide: Potential Use in Novel Therapeutic Interventions in Alcohol, Drugs, and Disease Mediated Cellular Toxicity by Targeting Cytochrome P450 2E1.
Review in Current drug metabolism, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 92 citations in OpenAlex.
- Compounds of plants with activity against SARS-CoV-2 targets.Expert review of clinical pharmacology · 2021Pooled it
- Allicin Bioavailability and Bioequivalence from Garlic Supplements and Garlic Foods.Nutrients · 2018Trial
- SLIT2 as a key regulator and therapeutic target in liver injury.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- Pharmacokinetic and phytochemical screening of Allium subhirsutum leaves for antimicrobial and anti-inflammatory properties.Scientific reports · 2025Article
- Natural Product-Induced Modulation of Androstenone Metabolism in Porcine Hepatocytes.Animals : an open access journal from MDPI · 2025Article
- Insights into garlic (Allium Sativum)'s nutrigenomics-associated fly-repellent potency in cattle.Tropical animal health and production · 2025Review
- Induction of Cyp2e1 contributes to asparaginase-induced hepatocyte sensitization to lipotoxicity.Acta pharmaceutica Sinica. B · 2025Article
- Inhibitory Effect of Two Carbonic Anhydrases Inhibitors on the Activity of Major Cytochrome P450 Enzymes.European journal of drug metabolism and pharmacokinetics · 2024Article
- Review
- Inhibition of endogenous hydrogen sulfide production reduces activation of hepatic stellate cells via the induction of cellular senescence.Cell cycle (Georgetown, Tex.) · 2024Article
- Impact of fresh grape juice on the pharmacokinetics of omeprazole: results of a food-drug interaction study.Frontiers in pharmacology · 2024Article
- Identification of Cytochrome P450 2E1 as a Novel Target in Glioma and Development of Its Inhibitor as an Anti-Tumor Agent.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- In vitro, in vivo, and in silico analysis of synbiotics as preventive interventions for lipid metabolism in ethanol-induced adipose tissue injury.Lipids in health and disease · 2023Article
- In Vitro Antitumor and Anti-Inflammatory Activities ofNutrients · 2023Article
- A review on the immunomodulatory properties of functional nutraceuticals as dietary interventions for children to combat COVID-19 related infections.Food production, processing and nutrition · 2023Review
- Anticancer Effect of Ruscogenin in B(a)P-Induced Lung Cancer in Mice via Modulation of Proinflammatory Cytokines and Mitochondrial Enzymes.Applied biochemistry and biotechnology · 2022Article
- Review
- A Whiff of Sulfur: One Wind a Day Keeps the Doctor Away.Antioxidants (Basel, Switzerland) · 2022Review
- In vitro evaluation of the inhibition potential of echinacoside on human cytochrome P450 isozymes.BMC complementary medicine and therapies · 2022Article
- Phytochemical Profiling ofPlants (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Diallyl sulfide (DAS) and other organosulfur compounds are chief constituents of garlic. These compounds have many health benefits, as they are very efficient in detoxifying natural agents. Therefore, these compounds may be useful for prevention/treatment of cancers. However, DAS has shown appreciable allergic reactions and toxicity, as they can also affect normal cells. Thus their use as in the prevention and treatment of cancer is limited. DAS is a selective inhibitor of cytochrome P450 2E1 (CYP2E1), which is known to metabolize many xenobiotics including alcohol and analgesic drugs in the liver. CYP2E1-mediated alcohol/drug metabolism produce reactive oxygen species and reactive metabolites, which damage DNA, protein, and lipid membranes, subsequently causing liver damage. Several groups have shown that DAS is not only capable of inhibiting alcohol- and drug-mediated cellular toxicities, but also HIV protein- and diabetes-mediated toxicities by selectively inhibiting CYP2E1 in various cell types. However, due to known DAS toxicities, its use as a treatment modality for alcohol/drug- and HIV/diabetes-mediated toxicity have only limited clinical relevance. Therefore, effort is being made to generate DAS analogs, which are potent and selective inhibitor of CYP2E1 and poor substrate of CYP2E1. This review summarizes current advances in the field of DAS, its anticancer properties, role as a CYP2E1 inhibitor, preventing agent of cellular toxicities from alcohol, analgesic drugs, xenobiotics, as well as, from diseases like HIV and diabetes. Finally, this review also provides insights toward developing novel DAS analogues for chemical intervention of many disease conditions by targeting CYP2E1 enzyme.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.